Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
30. Juli 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2024,...
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
05. Juni 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global...
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
04. Juni 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
09. Mai 2024 07:00 ET
|
Amicus Therapeutics, Inc.
1Q 2024 Total Revenue of $110.4M, a 28% Increase Year-over-Year Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at CER Raising Full-Year 2024 Galafold® Guidance on Continued Strong Demand ...
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
08. Mai 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2024 Health Care...
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
01. Mai 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 9, 2024, at...
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
20. März 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
01. März 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor...
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
28. Februar 2024 07:00 ET
|
Amicus Therapeutics, Inc.
2023 Total Revenue of $399.4M, a 21% Increase Year-over-Year Strong Patient Demand Continues for Pombiliti™ + Opfolda™ in the U.S., U.K., and Germany Projecting 2024 Galafold® Revenue Growth of...
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
15. Februar 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28,...